StandardX Raises £10M for Isotope Production

A significant seed funding round totaling £10 million has been secured by StandardX, a UK-based deep technology firm. The investment, spearheaded by prominent venture capital firms Vsquared Ventures and East X Ventures, with participation from firstminute capital, UK Innovation and Science Seed Fund (UKI2S), Brevan Howard Macro Venture, and Geometry, will fuel the development of novel isotope production systems. This capital infusion positions StandardX to establish what it claims will be the world's first scalable isotope refinery.

The company's immediate strategic focus is on the production of critical rare isotopes essential for advanced cancer diagnostics and therapies. This aligns with a growing global demand for radiopharmaceuticals, a sector projected to see substantial growth driven by an anticipated 67% increase in new cancer cases by 2050. StandardX's proprietary accelerator-based technology aims to overcome existing supply chain bottlenecks that currently hinder research and patient access to life-saving treatments. The firm anticipates delivering its initial medical isotopes to a research partner by 2027, with broader industrial-scale output targeted from 2029.

Beyond its healthcare applications, StandardX is also charting a course into the burgeoning fusion energy sector. The company plans to leverage its advanced manufacturing capabilities to produce tritium, a key fuel component for next-generation fusion power plants. The current global tritium supply is extremely limited, estimated at just 25 kilograms, while a single commercial fusion facility could require tens of kilograms annually. StandardX has already forged agreements with fusion energy developers, signaling its intent to become a vital supplier as the industry matures.

Founded in 2025 by experienced nuclear engineers Richard Pearson and Ross Allen, StandardX is building a standardized industrial platform designed for flexible, multi-isotope manufacturing. This approach contrasts with traditional, often single-purpose isotope production facilities, which are frequently aging and geographically concentrated. The company envisions a decentralized production network, bringing manufacturing closer to end-users and enhancing supply chain resilience. The newly acquired funding will be instrumental in establishing StandardX's inaugural industrial site in London, where the first refinery system will be deployed.

The global market for isotopes, while often overlooked, is fundamental to numerous high-growth industries. In healthcare alone, isotopes are indispensable for diagnostic imaging techniques like PET scans and SPECT, as well as for targeted radiation therapies. The limited production capacity and complex regulatory environment have historically constrained innovation. StandardX's ambition to create a flexible, scalable production infrastructure could unlock significant advancements, particularly in areas like targeted alpha therapies, which offer greater precision in cancer treatment by delivering radiation directly to malignant cells.

The team behind StandardX brings a wealth of expertise, with members having prior experience at organizations such as SpaceX, The London Clinic, Oxford University, Cambridge University, Fermilab, and the UK Atomic Energy Authority. This funding will support the expansion of their team, further engineering development, and the scaling of production capabilities. The strategic dual focus on immediate medical needs and future energy solutions underscores StandardX's potential to address critical global challenges.